Summary
We examined whether tolbutamide has any acute or short-term effects on insulin action in Type 1 (insulin-dependent) diabetes. A euglycaemic glucose clamp was performed in seven Type 1 diabetic patients without clinical insulin resistance by infusing glucose at a constant rate of 0.01 mmol·kg-1·min-1 for 3 h together with a simultaneous insulin infusion using an ‘artificial pancreas’. The insulin infusion rate required to maintain blood glucose at 6.7 mmol/l at a set low glucose infusion rate provides an index of insulin action in vivo. The euglycaemic clamp was performed on 3 separate days in the same patient: (1) in the basal state; (2) during simultaneous intravenous tolbutamide infusion of 0.5 g/h, and (3) after treatment with 2.5 g tolbutamide/day for 6 days in addition to insulin. The insulin infusion rate needed to maintain the set blood glucose level did not differ significantly between the three experimental conditions (1.2±0.2 versus 1.3±0.3 versus 1.2±0.3 U/h). Plasma glucagon, growth hormone, non-esterified fatty acid and glycerol levels did not differ between control or sulphonylurea treatment studies. The results suggest that tolbutamide does not exert any acute or short-term effects on insulin action in vivo in Type 1 diabetes. Our results do not provide support for the idea that this agent is a clinically useful adjunct to insulin in such patients.
Article PDF
Similar content being viewed by others
References
Lebovitz HE, Feinglos MN (1978) Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1: 189–198
Ratzmann KP (1983) Neue Aspekte in der Therapie des Diabetes mellitus mit Sulfonylharnstoffen? Dtsch Gesundheitswes 38: 1109–1114
Putnam WS, Andersen DK, Jones RS, Lebovitz HE (1981) Selective potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea glipizide. J Clin Invest 67: 1016–1023
Feinglos MN, Lebovitz HE (1980) Sulfonylurea treatment of insulin-independent diabetes mellitus. Metabolism 29: 488–494
Greenfield MS, Doberne L, Rosenthal M, Schulz B, Wiedstrom A, Reaven GM (1982) Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes 31: 307–312
Schulz B, Ratzmann KP, Heinke P, Besch W (1983) A stimulatory effect of tolbutamide on the insulin-mediated glucose uptake in subjects with impaired glucose tolerance. Exp Clin Endocrinol 82: 222–231
Butterfield WJH, Arab MMH, Buckle ALJ, Chlouverakis C, Hanley T, Mahler RF, Whichelow MJ (1962) The mechanisms of action of tolbutamide. Observations on the effects of sulfonylureas on peripheral metabolism in man. Diabetes 11: 43–49
Cahill GF, Hastings AB, Ashmore J (1975) Effects of substituted sulfonylureas on rat diaphragm and liver tissue. Diabetes 6: 26–27
Fry IK, Wright GF (1957) The action of hypoglycemic sulfonylureas on carbohydrate metabolism in the fasted rat. J Pharmacol 12: 350–355
Grunberger G, Ryan J, Gorden PH (1982) Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetic. Diabetes 31: 890–896
Musbah MO, Furman BL (1980) In vitro metabolic effects of gliclazide and glibenclamide in the rat. J Pharm Pharmacol 32: 550–533
Seltzer HS (1962) Quantitative effects of glucose, sulfonylureas, salicylate, and indol-3-acetic acid on the secretion of insulin activity into pancreatic venous blood. J Clin Invest 41: 289–300
Ward EA, Ward GM, Turner RC (1981) Effect of sulfonylurea on insulin secretion and glucose control in insulin-treated diabetics. Br Med J 283: 278–281
Zinman B, Ogilvie RJ (1972) The acute effects of tolbutamide on forearm metabolism. J Clin Endocrinol Metab 35: 299–306
Harano Y, Ohgaku S, Kosugi K, Yasuda H, Nakano T, Kobayashi M, Hidaka H, Izumi K, Kashiwagi A, Shigeta Y (1981) Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin and somatostatin infusion. J Clin Endocrinol Metab 52: 982–987
Olefsky JM (1980) Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes 30: 148–162
Ratzmann KP, Schulz B, Besch W, Witt S (1981) Evaluation of insulin resistance during inhibition of endogenous insulin and glucagon secretion by somatostatin in non-obese subjects with asymptomatic diabetes. Diabetologia 21: 192–197
Ratzmann KP, Witt S, Schulz B (1982) Evaluation of insulin resistance in non-obese subjects with impaired glucose tolerance. Diabete Metab 8: 223–228
DeFronzo RA, Hendler R, Simonson D (1982) Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 31: 795–801
DeFronzo RA, Simonson D, Ferranini E (1982) Hepatic and peripheral insulin resistance: a common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23: 313–319
Fantus IG, Rayn J, Gordon PH (1981) The insulin receptor in insulin-dependent diabetes mellitus. An in vivo and in vitro study. Metabolism 30: 510–517
Maloff BL, Lockwood DH (1981) In vitro effects of a sulfonylurea on insulin action in adipocytes. J Clin Invest 68: 85–90
Besch W, Ziegler M, Keilacker H, Woltanski KP (1979) Radioimmunologische Bestimmung des Human-C-Peptides im Plasma. Radiobiol Radiother (Berl) 20: 816–817
Lambert AK, Layekes Y, Zahnd GR (1967) Improvement of human growth hormone immunoassay using 125I. Proc Soc Exp Biol Med 126: 405–409
Schulz B, Ziegler M, Witt S, Rjasanowski I, Heinke P, Bibergeil H (1978) Regulation of pancreatic glucagon secretion during a continuous glucose infusion in early and overt diabetics. Acta Endocrinol (Copenh) 89: 329–338
Duncombe WC (1964) The colorimetric micro-determination of non-esterified fatty acids in plasma. Clin Chim Acta 9: 122–125
Eggstein M, Kreutz FH (1966) Eine neue Bestimmung der Neutralfette in Blutserum und Geweben. Prinzip, Durchführung und Besprechung der Methode. Klin Wochenschr 44: 262–267
Blumenthal SA (1977) Potentiation of the hepatic action of insulin by chlorpropamide. Diabetes 26: 485–489
Colwell AR (1964) Potentiation of insulin action on the liver by tolbutamide. Metab Clin Exp 13: 1310–1317
Daniels EL, Lewis SB (1982) Acute tolbutamide administration alone or combined with insulin enhances glucose uptake in the perfused rat hindlimb. Endocrinology 110: 1840–1842
Feldman JM, Lebovitz HE (1969) An insulin dependent effect of chronic tolbutamide administration on the skeletal muscle carbohydrate transport system. Diabetes 18: 84–95
Feldman JM, Lebovitz HE (1969) Appraisal of the extra-pancreatic action of sulfonylureas. Arch Int Med 123: 314–322
Greestein BD (1979) Improved insulin receptor assay: Effects of an antidiabetic sulfonylurea on liver membrane insulin receptors from obese hyperglycaemic mice. Br J Pharmacol 66: 317–322
Beck-Nielsen H, Pederson O, Lindskov HO (1979) Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol (Copenh) 90: 451–462
Olefsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leucocytes of diabetic patients. Am J Med 60: 89–95
Prince MJ, Olefsky JM (1980) Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. J Clin Invest 66: 608–611
Fleig WE, Nöther-Fleig G, Fußgänger RD, Ditschuneit H (1982) Effekt von Insulin und Glibenclamid auf die Insulinbindung von Hepatozyten in vitro. Verh Dtsch Ges Inn Med 88: 796–798
Vigneri R, Pezzino V, Wong KY, Goldfine ID (1982) Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding to its receptor target cells. J Clin Endocrinol Metab 54: 95–100
Wajngot A, Luft R, Vranic M, Efendic S (1982) Glucose metabolism in the basal state and during a two-hour glucose infusion in low insulin responders and controls. Horm Metab Res 14: 564–568
Ratzmann KP, Witt S, Heinke P, Schulz B (1982) The effect of ageing on insulin sensitivity and insulin secretion in non-obese healthy subjects. Acta Endocrinol (Copenh) 100: 543–549
Ratzmann KP, Witt S, Schulz B (1983) Further support for heterogeneity of insulin response and insulin sensitivity in non-obese subjects with glucose intolerance. Acta Endocrinol (Copenh) 102: 410–415
Christiansen JS, Svendsen PA, Mathiesen E, Rubin P, Deckert T (1981) Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial beta cell and during conventional therapy. Horm Metab Res 13: 537–541
Perlman K, Ehrlich RM, Filler RM, Albisser AM (1981) Waveform requirements for metabolic normalization with continuous intravenous insulin delivery in man. Diabetes 30: 710–717
Schade DS, Eaton RP, Spencer W (1980) Normalization of plasma insulin profiles in diabetic subjects with programmed insulin delivery. Diabetes Care 3: 9–14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratzmann, K.P., Schulz, B., Heinke, P. et al. Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes. Diabetologia 27, 8–12 (1984). https://doi.org/10.1007/BF00253493
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00253493